http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2059235-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd83355688b4fa3c4f5b3318e5de63c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b34b616e4c337305ceae7d1cb87e9ef8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2007-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbcc75c78e19363fe3932ca3ffb693df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ecfaf33a2fe76c80f44500161930d1b |
| publicationDate | 2009-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2059235-A2 |
| titleOfInvention | Method for prevention and treatment of alzheimers |
| abstract | Elderly individuals are administered dosages of Trans-resveratrol totaling between about 250 mg and 1 gram per day. Typically about 500 mg of Trans-resveratrol are orally administered to such individuals on a daily basis. As a result of the chemical action of Trans-resveratrol in the bodies of the subjects, Alzheimer's disease is prevented, or if already present, advancement is retarded and the existing mentally debilitating conditions of Alzheimer's disease are treated. A subject receiving the Trans-resveratrol experiences a reduction or illumination of the effects of Alzheimer's disease. |
| priorityDate | 2006-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.